Atıf Formatları
Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

M. ERAKSOY Et Al. , "Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study," 19th World Congress of Neurology , vol.285, Bangkok, Thailand, 2009

ERAKSOY, M. Et Al. 2009. Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study. 19th World Congress of Neurology , (Bangkok, Thailand).

ERAKSOY, M., Akman-Demir, G., Agan, K., Gunal, D., Us, O., Saip, S., ... Demirci, N. O.(2009). Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study . 19th World Congress of Neurology, Bangkok, Thailand

ERAKSOY, Mefküre Et Al. "Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study," 19th World Congress of Neurology, Bangkok, Thailand, 2009

ERAKSOY, Mefküre Et Al. "Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study." 19th World Congress of Neurology , Bangkok, Thailand, 2009

ERAKSOY, M. Et Al. (2009) . "Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study." 19th World Congress of Neurology , Bangkok, Thailand.

@conferencepaper{conferencepaper, author={Mefküre ERAKSOY Et Al. }, title={Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study}, congress name={19th World Congress of Neurology}, city={Bangkok}, country={Thailand}, year={2009}}